QUANTAIRA and Daisy Global: What Is the Connection to EndoTech? The Story Behind the New AI Trading Platform

Independent investigation | 12 November 2026 | Cryptocurrency, AI trading and investment research

QUANTAIRA is being promoted as a new generation of AI-powered automated trading. But there is more to the story than algorithms, cryptocurrency exchanges and promises of passive income. Its connection with EndoTech and the Daisy Global community raises some important questions that prospective participants should understand before getting involved.

When a new investment opportunity appears, most people naturally concentrate on what it promises to deliver.

How much could I earn? How does the technology work? How much money do I need to start? Can I withdraw whenever I want?

Those are reasonable questions.

But sometimes the more important questions concern the history behind the opportunity.

Who developed the technology? Who introduced it to the market? Who has been involved in its development? And what happened before the latest platform came along?

That is exactly what makes the emergence of QUANTAIRA interesting.

The company is presenting a new AI trading proposition involving EndoTech and CoinZoom. However, public information also reveals a significant connection with the Daisy Global community, a name that has previously attracted regulatory attention.

I wanted to understand that relationship.

This is what I found.

1. First, what exactly is QUANTAIRA?

QUANTAIRA is an emerging automated trading platform built around cryptocurrency trading technology.

Its promotional material identifies two important technology partners:

• EndoTech: The company associated with the quantitative trading algorithms and AI technology.

• CoinZoom: The cryptocurrency exchange infrastructure through which participants are expected to access the trading arrangement.

The proposition is attractive.

Participants are told that they can access automated trading technology while keeping their funds in their own CoinZoom accounts.

The marketing also refers to community rewards, automatic compounding and the opportunity to participate without having to become an experienced trader.

The QUANTAIRA Telegram channel describes the project as an AI auto-trading platform powered by EndoTech and CoinZoom.

It also promotes the launch of what is described as EndoTech 2.0.

But why is Daisy Global appearing so prominently in the background?

To understand that, we need to go back a little.

2. The Daisy Global connection

D.AI.SY, also known as Daisy Global, was promoted as a decentralised AI trading community.

Its proposition involved crowdfunding and the development of artificial intelligence technology for automated forex and cryptocurrency trading.

The project attracted an international community of participants and promoters.

A particularly important part of its proposition was the involvement of EndoTech.

In fact, historical Daisy promotional presentations described participants contributing towards the development and testing of EndoTech’s AI algorithms.

The June 2022 presentation discussed:

• Funding the development of AI trading algorithms.

• Rewards associated with algorithmic trading activity.

• Proposed equity in EndoTech.

• Potential dividends and future business development.

These were promotional statements and proposed arrangements, not proof that every participant received shares or that promised returns materialised.

Nevertheless, they help explain why EndoTech became such an important name within the Daisy community.

Read the historical D.AI.SY presentation.

3. The regulatory history of Daisy Global

On 20 November 2023, the British Columbia Securities Commission published an investor warning concerning D.AI.SY, also known as Daisy Global.

The regulator stated that Daisy advertised crowdfunding packages directing between 50% and 100% of the proceeds into investment funds trading forex and cryptocurrency using an AI-driven algorithmic trading system.

The BCSC also stated that Daisy was not registered to trade in or advise on securities or derivatives in British Columbia.

It urged residents to exercise caution.

Read the BCSC warning dated 20 November 2023.

There was also regulatory attention in Alberta.

On 12 December 2023, the Alberta Securities Commission added D.AI.SY Global to its Investment Caution List.

The regulator stated that Daisy was not registered to trade in or advise on securities or derivatives in Alberta.

Read the Alberta Securities Commission entry.

These warnings concern Daisy Global and its activities in those jurisdictions. They are not findings that QUANTAIRA has committed wrongdoing.

However, they form part of the publicly documented history of the community from which QUANTAIRA is now being promoted.

That history deserves to be understood.

4. EndoTech: The common thread

It is the technology company associated with the AI trading systems being promoted through QUANTAIRA.

Its own website describes a software platform that enables business customers to use algorithmic investment technology.

Visit EndoTech.

But EndoTech also has its own regulatory history.

In April 2021, Belgium’s Financial Services and Markets Authority (FSMA) published a warning about companies offering automated trading software, commonly called Expert Advisors.

The warning included EndoTech among the websites offering such software in Belgium.

The FSMA raised concerns about companies offering these services without the required authorisation and highlighted the risks associated with multi-level marketing structures used to distribute trading software.

It also warned about the substantial risks associated with CFDs, forex and cryptocurrency derivatives.

This is important background.

However, the warning dates from 2021 and concerns the activities described by the regulator at that time. It does not establish that EndoTech’s current technology or QUANTAIRA is operating unlawfully.

Read the FSMA warning reproduced by Norway’s financial regulator.

The question I would now ask is straightforward:

What has changed between the earlier EndoTech business model and the technology now being introduced through QUANTAIRA?

That deserves a clear explanation.

5. Did Daisy Global members have an ownership interest in EndoTech?

This is particularly interesting.

Promotional communications published through the Daisy community have repeatedly stated that Daisy participants collectively own an interest in EndoTech.

For example, a Daisy Global Telegram announcement promoting EndoTech 2.0 stated that members owned part of EndoTech and that dividends would be paid as the company grew.

Other Daisy-related publications discussed a proposed shareholding arrangement and a website where members could view their EndoTech shares.

However, there is something important to establish here.

These are statements made in promotional and community communications. They do not independently establish the legal ownership structure, the number of shares issued, the identity of shareholders or whether any dividends have actually been paid.

I have not located sufficient independent corporate documentation to verify the precise ownership arrangements.

That is something I would like to see clarified.

If members genuinely own equity in EndoTech, they should be able to establish exactly what they own, through which legal entity, and what rights accompany that ownership.

6. How did QUANTAIRA enter the picture?

Public promotional material from the Daisy community began discussing QUANTAIRA in 2026.

An October 2026 publication described an exclusive partnership between EndoTech and QUANTAIRA to introduce a new trading platform and community rewards arrangement.

It promoted several features:

• No joining fee.

• No upfront platform fee.

• Funds held in CoinZoom accounts.

• Automated trading.

• Automatic compounding.

• Withdrawals without a stated lock-up period.

• A community rewards programme.

It also stated that a referral link would be required to join.

There is another interesting development.

The QUANTAIRA promotional material describes a beta launch and an anticipated wider rollout in 2027.

A November update published through the Daisy-related website describes pre-registration opening on 11 November 2026, with quality assurance testing and legal documentation still being finalised.

One qualification is necessary: DaisyDapp explicitly says that it is not an official Daisy Global website. Its articles are useful leads, but they should not be treated as formal corporate announcements.

The QUANTAIRA-branded Telegram channel provides further evidence of the EndoTech relationship.

Taken together, the public material shows a clear promotional connection between the Daisy community, EndoTech and the launch of QUANTAIRA.

What it does not establish is that QUANTAIRA is legally owned or operated by Daisy Global.

That would require corporate documentation.

7. The rewards programme: What are members being told?

One of the more interesting aspects of the QUANTAIRA proposition is its community rewards structure.

Promotional material published through the Daisy-related websites refers to 15% of trading profits being returned to the community.

Other material also refers to 60% of trading fees being allocated to the community.

These figures appear in different promotional descriptions and should not automatically be assumed to represent the same payment arrangement.

The full contractual rewards plan is needed.

There are several questions worth answering:

1. How are the rewards calculated?

2. Are they based on realised trading profits?

3. How are trading losses accounted for?

4. What proportion goes to individual participants?

5. Are referral commissions included?

6. Can participants receive rewards without recruiting others?

7. What happens if the trading system stops generating profits?

These are perfectly reasonable questions.

A rewards programme should be easy to understand, particularly when people are being encouraged to introduce friends and family.

I would like to see the complete published compensation plan before drawing conclusions about its sustainability.

8. Is QUANTAIRA simply a new version of Daisy Global?

This is where I would be careful.

There are clearly overlapping names, communities and promotional relationships.

Daisy-related channels have promoted QUANTAIRA.

EndoTech is central to both the historical Daisy AI trading proposition and the new QUANTAIRA platform.

Promotional material also refers to EndoTech 2.0.

But I have not found sufficient evidence to establish that QUANTAIRA is simply a rebranded Daisy Global, that it has assumed Daisy’s previous legal obligations, or that the two have the same ownership or management.

Those claims would go beyond what the public information establishes.

What can reasonably be said is that QUANTAIRA is being introduced to an audience that includes the existing Daisy community, with EndoTech technology forming a major part of the proposition.

That is a meaningful connection.

It also means that anyone considering QUANTAIRA should understand the earlier history rather than treating it as a completely unrelated new project.

9. What about the risks for new participants?

There are several issues I believe deserve attention.

Trading performance

Where are the independently audited results for the new EndoTech 2.0 system?

I would want to see live trading performance, maximum drawdown, losing months and the actual risks involved.

Control of funds

The claim that funds remain in CoinZoom accounts is attractive. However, participants need to understand the exchange’s custody arrangements, API permissions and withdrawal procedures.

QUANTAIRA and Daisy Global: What Is the Connection to EndoTech? The Story Behind the New AI Trading Platform

Regulatory position

The regulatory requirements depend on the actual services provided, the legal entities involved and the countries where participants reside.

A company operating internationally cannot simply assume that the same arrangements are acceptable everywhere.

Previous history

The regulatory warnings concerning Daisy Global and the earlier EndoTech software offering should be considered when evaluating the background of the technology and its distribution.

Business model

The rewards programme needs to be examined alongside the underlying trading economics.

No amount of referral activity can turn an unprofitable trading strategy into a sustainable investment business.

10. My conclusion: The history.

I think QUANTAIRA deserves closer scrutiny.

Not because I can establish that it is fraudulent. I cannot.

Not because AI trading is inherently problematic. It isn’t.

And not because a company should be prevented from developing new technology.

The reason is much simpler.

There is a publicly documented history involving Daisy Global, EndoTech and automated trading technology.

There are previous regulatory warnings that prospective participants should know about.

There are claims about community ownership, trading profits and rewards that deserve proper documentation.

And there are important questions about the legal and commercial arrangements behind the new platform.

I would like to see QUANTAIRA succeed if it genuinely delivers a transparent, effective and properly operated trading service.

But success should be measured by independently verifiable trading performance, sound risk management and a business structure that stands up to scrutiny.

It should not be measured by the number of people registering, the size of a referral network or the excitement surrounding a launch.

What I would like QUANTAIRA and EndoTech to clarify

Here are the questions I believe deserve public answers:

1. What is the exact legal relationship between QUANTAIRA and EndoTech?

2. What is the relationship between QUANTAIRA and the former Daisy Global community?

3. Can the claimed EndoTech shareholdings of Daisy participants be independently verified?

4. Who owns the intellectual property behind EndoTech 2.0?

5. Where can the independently audited trading results be examined?

6. What are the maximum historical drawdowns?

7. How does the community rewards programme work in full?

8. Which countries can participate, and what regulatory arrangements apply?

These are not unreasonable demands.

They are the questions any responsible person should ask before committing money to an automated trading opportunity.

People deserve to know the full story

There is nothing wrong with being excited about new technology.

There is nothing wrong with wanting to generate additional income.

And there is nothing wrong with exploring opportunities that might make financial markets more accessible.

But people should never be expected to make financial decisions based on incomplete information.

If a platform has a history, prospective participants deserve to understand it.

If a technology has previously been used in other business models, people deserve to know that too.

If a community rewards programme is being promoted, its economics should be clear.

And if an automated trading system claims to generate profits, those claims should be backed by evidence.

My advice is simple: learn the history, investigate the people and companies involved, understand the risks and demand evidence before committing your money.

Because when it comes to people’s financial security, unanswered questions matter.

And people deserve to be protected.

Editorial note: This article is based on publicly available company material, community publications and regulatory records available as of 12 November 2026. Some Daisy-related publications are not official corporate communications. Regulatory warnings concerning Daisy Global and EndoTech relate to the entities and activities identified by the regulators at the time; they are not findings against QUANTAIRA. No allegation of fraud or unlawful conduct is made against QUANTAIRA.